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The insulin/insulin-like growth factor (IGF) system is a major determinant in the patho-
genesis and progression of colorectal cancer (CRC). Indeed, several components of this 
signaling network, including insulin, IGF-1, IGF-2, the IGF-binding proteins, the insulin 
receptor (IR), the IGF-1 receptor (IGF-1R), and IR substrate proteins 1 and 2 contribute 
to the transformation of normal colon epithelial cells. Moreover, the insulin/IGF system is 
also implicated in the development of resistance to both chemotherapeutic drugs and 
epidermal growth factor receptor targeted agents. The identification of hybrid receptors 
comprising both the IR and IGF-1R adds further complexity to this signaling network. 
Thus, a comprehensive understanding of the biological functions performed by each 
component of the insulin/IGF system is required to design successful drugs for the 
treatment of CRC patients.
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inTRODUCTiOn
The insulin/insulin-like growth factor (IGF) system is a multifactorial signaling network that modu-
lates energy metabolism, cell growth, and cancer (1).
To date, two insulin receptor (IR) isoforms have been described. They differ for the presence of 
a short exon 11 that can be excised from (IR-A, short isoform) or included in (IR-B, long isoform) 
the IR coding sequence as a result of alternative splicing (2). Proteolysis of an IR protein precursor 
generates the mature receptor consisting of two alpha and two beta subunits that form a hetero-
tetrameric structure. The alpha subunits display extracellular localization and are responsible for 
ligand binding. The beta subunits exhibit a trans-membrane segment and an intracellular portion 
containing the tyrosine kinase domain. While glucose uptake remains the main IR-mediated func-
tion, a growing body of evidence suggests that the two IR isoforms have different biological roles with 
IR-A mostly exerting mitogenic effects and IR-B modulating cell metabolism (3). This hypothesis is 
supported by the different ligand-binding ability of the isoforms (IR-A recognizes both insulin and 
IGF-2 with equal affinity, while IR-B primarily binds insulin), and by their diverse tissue distribution 
(IR-A is more expressed in fetal and cancer tissues, while IR-B is predominant in muscle, liver, and 
fat) (Figure 1A) (4).
The IGF-1 and IGF-2 receptors (IGF-1R/IGF-2R) show different structures. IGF-1R is homologous 
to the IR and preferentially binds IGF-1 or IGF-2 over insulin. Otherwise, IGF-2R has a monomeric 
structure and lacks the catalytic activity. Moreover, this receptor binds only IGF-2, internalizes it, 
and induces its lysosomal degradation (5). IGF-1R is involved in the regulation of body growth in 
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response to pituitary-released growth hormone (GH). However, 
activation of IGF-1R can also regulate cell proliferation, survival, 
and angiogenesis (3, 6, 7). A family of six circulating IGF-binding 
proteins (IGFBPs) may act as tumor suppressors by limiting IGFs 
activity (5), although Firth et al. have suggested that IGFBPs may 
also have IGF-independent effects on cancer growth (8).
IR/IGF-1R hybrid receptors (HRs) have been identified in 
both immortalized cell lines and human tissues. Specifically, two 
HRs may be generated by the interaction of the IGF-1R with 
either IR-A or IR-B. While the intracellular signaling of HRs is 
not completely understood, it is well known that IR-A/HRs are 
activated by both insulin and IGFs – although they bind the latter 
with higher affinity – unlike IR-B/HR that only recognize IGFs 
(Figure 1A). The current hypothesis is that the preferential asso-
ciation of IR-A or IR-B with the IGF-1R essentially depends on the 
relative abundance of the two IR isoforms in each tissue (9, 10).
Breast, ovarian, prostate, lung, and colon cancer are the tumor 
tissues where the insulin/IGF system has been directly linked to 
tumor development and progression (5, 6). This review will dis-
cuss the role of the insulin/IGF system in colorectal cancer (CRC).
THe inSULin/iGF SYSTeM in 
COLOReCTAL CAnCeR
The insulin/IGF system is a critical determinant of CRC devel-
opment, and also displays important prognostic implications 
FiGURe 1 | expression and function of the insulin/iGF system in normal and colorectal cancer cells. (A) In normal tissue insulin, IGF-1 and IGF-2 bind with 
high (continuous line) or low (dashed line) affinity to their corresponding receptors and activate specific IRSs, which modulate several pathways involved in gene 
transcription, cell proliferation, and apoptosis. IGFBPs act as negative regulators that modulate both IGF-1 and IGF-2 functions. (B) In colorectal cancer high IR-A 
and IGF-1R expression (upward arrow) as well as IRS-1 and IRS-2 polymorphisms are involved in up-regulation of the PI3K-Akt pathway. Moreover, IGFPB3 
down-regulation (downward arrow) as well as IGFBP2 overexpression (upward arrow) are involved in strengthening IGF-1 functions and in the activation of 
intracellular signaling pathways that contribute to alter gene transcription, cellular proliferation, differentiation, and apoptosis.
for patients diagnosed with the disease. Indeed, in 2001 
Giovannucci and colleagues suggested that multiple markers 
of hyperinsulinemia (e.g., low physical activity, high body 
mass index, central adiposity, and high IGF-1 levels) correlate 
with higher risk of CRC. In their study, CRC incidence was 
invariably increased after the advent of sedentary lifestyles 
associated with obesity, and higher availability of processed 
carbohydrates and saturated fatty acids (11). Moreover, it has 
been demonstrated that the increased blood levels of insulin 
in type II diabetes individuals, caused by insulin-resistance, 
enhance the risk to develop colon cancer (12). In addition, 
Yang et  al. observed further elevated incidence of CRC in 
diabetic subjects under insulin treatment (13). These results 
were not surprising as previous evidence had shown that insu-
lin provides mitogenic and pro-angiogenic signals for normal 
colorectal epithelial cells, possibly increasing their energetic 
metabolism (14, 15).
An additional study later showed that phosphorylated IR (pIR) 
is expressed at significantly higher frequencies in low-grade car-
cinomas, such as in primary specimen from non-small cell lung 
cancer patients (16), and that higher insulin levels are also evident 
in patients with dysplastic lesions. Accordingly, Abruzzese and 
colleagues found high pIR-positive staining during the transi-
tion from normal colorectal epithelium to colon adenomas and 
adenocarcinomas, with strong pIR expression in adenomas and 
low-grade adenocarcinomas, suggesting that activation of the 
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insulin/IR axis is an early event in colorectal carcinogenesis 
(Figure 1B) (17).
Signaling downstream of the insulin/IR complex by the insulin 
receptor-1 and -2 substrates (IRS-1, IRS-2) is also a critical deter-
minant of CRC aggressiveness. Specifically, IRS-1 expression 
appears inversely correlated to CRC differentiation, supporting 
a role for IRS-1 in CRC progression and liver metastasis since 
IRS-1 immunostaining is significantly higher in hepatic metasta-
ses relative to both primary CRC and paired colonic epithelium 
(18). Likewise, IRS-2 mRNA and protein expression positively 
correlates with normal colorectal epithelium transitioning to 
adenoma and, subsequently, to adenocarcinoma. Furthermore, 
IRS-2 overexpression activates the oncogenic PI3 kinase pathway 
leading to Akt phosphorylation and reduced cell adhesion, both 
characteristics of invasive CRC cells (Figure 1B) (19). IRS-1 and 
IRS-2 polymorphisms have also been independently associated 
with increased CRC risk (20). In fact, the presence of at least one 
R allele (GR or RR) in IRS-1 position 972 is associated with a 
higher incidence of CRC. On the contrary, IRS-2 heterozygosity 
in position 1057 (GD genotype) significantly reduces the risk of 
developing CRC. Esposito et  al. have also analyzed the coding 
region and short intron-exon borders of both IRS-1 and IRS-2 
in 14 CRC cell lines and 33 primary specimens. They identified 
21 IRS-1 variants and 18 IRS-2 variants with 7 novel IRS-2 vari-
ants, including 4 missenses, 2 in-frame insertion mutations, and 
1 silent variant (21). If and how these variants may be involved 
in the modulation of IRS-2 function in colorectal tumorigenesis 
remains to be established.
Initial interest for a possible role of IGF-1 in colon cancer 
development stemmed from observations reporting an increased 
CRC incidence in patients with acromegaly, a condition char-
acterized by elevated levels of both GH and IGF-1 (22, 23). 
This potential link was further supported by work from Lahm 
and colleagues that described frequent IGF-1R overexpression 
in human colon cancer cells (24). Because it is currently well 
established that IGF-1 is mostly bound to IGFBP3, the finding 
that mean IGF-1 levels are higher in CRC patients as compared 
to normal subjects while IGFBP3 is lower in patients than in 
healthy individuals strongly suggests a positive association and 
a negative association of these two proteins with CRC risk (25). 
These data are also confirmed by several prospective cohort (26, 
27) and case-control studies (28, 29). In addition, blood concen-
trations of IGF-1 have been associated with the risk of prostate 
and premenopausal breast cancer (30–33), while no significant 
association of circulating IGF-1/IGFBP3 has been related with 
ovarian cancer risk (34).
The role of IGF-2 and IGFBP2 in CRC development has 
been thoroughly investigated by Renehan and colleagues. 
They examined 92 patients with colon cancer and found mean 
IGF-2 SD scores (SDS) marginally elevated compared with 
normal colonoscopy controls. However, mean IGFBP2 SDS 
were significantly higher in the cancer population compared to 
controls. Moreover, when considered by disease stage, IGFBP2 
SDS significantly increased from early to advanced disease but 
fell rapidly in patients subjected to curative resection (29). In 
an additional study, the same group demonstrated that plasma 
IGFBP2 levels distinguished patients with CRC and advanced 
colon polyps from healthy subjects. Furthermore, as reported 
by Liou and colleagues, higher IGFBP2 plasma levels were inde-
pendently associated with inferior overall survival (OS) of CRC 
patients (35).
Insulin-like growth factors activate the IGF-1R, which is 
frequently overexpressed in cancer cells triggering a number 
of intracellular signaling cascades that enhance cell cycle pro-
gression and inhibit apoptosis. Indeed, preliminary findings 
indicate that IGF-1 and its receptor promote both the growth 
and malignant transformation of adenomatous polyps (36). In 
further experiments, a human CRC cell line overexpressing the 
IGF-1R – HCT116/IGF-1R – resulted in highly invasive tumor 
and produced distant metastases in murine models, whereas the 
parental cell line did not. Moreover, IGF-1R overexpression was 
associated with Akt activation and up-regulation of the anti-
apoptotic protein Bcl-xL (Figure 1B) (37). A further study showed 
that IGF1-R is also involved in the activation of β-catenin in CRC 
cells. In fact, knockdown of IGF-1R inhibited human CRC cells 
growth and downstream PI3K and Akt that, in turn, caused the 
activation of GSK3ß. This protein inhibited β-catenin transloca-
tion into the nucleus and the transcription of cell proliferation 
genes (Figure 1B) (38). Additional data also suggest that both p63 
and p73, members of the p53-family, may control colon cancer 
proliferation via mechanism/s that involve down-regulation of 
the IGF-1R gene. Using transient co-expression assays in colon 
cancer-derived HCT116, Nahor et al. showed that both proteins 
inhibit the IGF-1R promoter reducing endogenous IGF-1R levels 
in a dose-dependent manner. Since mutant p63 and p73 are 
impaired in their ability to suppress IGF-1R expression, these 
findings further support a causative role for this receptor in CRC 
(39). Finally, miR-143 and miR-145 have been recently found to 
target the 3′ UTR of the IGF-1R. Expectedly, there was an inverse 
correlation between miR-143/145 levels and IGF-1R expression 
in CRC. Furthermore, miR-145 also targets the 3′ UTR of IRS-1 
and its overexpression dramatically inhibits the growth of colon 
cancer cells (40, 41).
As for HRs, IR-A/HR is the predominant isoform in most 
cancer cell lines. In 1999, Frasca et al. reported that IR-A relative 
abundance was significantly higher in CRC tissues as compared 
to normal colonic epithelial cells, with median values ranging 
from 68–73% in cancer to 35–43% in normal tissue (42). By 
employing the Sox9-EGFP reporter mice, Andreas and colleagues 
described cell-type-specific differences in IR isoform expression 
and functions in the intestinal epithelium. They found that IR-A 
was the predominant isoform in both the undifferentiated intesti-
nal epithelial stem cells and in the rapidly dividing progenitors of 
the crypt, whereas IR-B expression was increased in post-mitotic 
entero-endocrine cells and intestinal epithelial cells enriched for 
other post-mitotic differentiated lineages (43).
THe inSULin/iGF SYSTeM in 
ReSiSTAnCe TO COLOReCTAL CAnCeR 
THeRAPY
Colorectal cancer is the second leading cause of cancer-related 
death in the Western population. Almost 25% of patients present 
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metastatic disease at diagnosis, displaying a dismal median OS 
of 7 months if deprived of appropriate medical treatment (44). 
However, in recent years, significant improvements in patient 
survival have been achieved largely due to the emergence 
of targeted molecular therapies that complement standard 
chemotherapeutic regimens. The availability of these biologic 
agents has increased the median OS of metastatic CRC to about 
30  months (45). For example, cetuximab and panitumumab, 
two anti-epidermal growth factor receptor (EGFR) monoclonal 
antibodies, have been proven efficacious in a subset of patients 
with metastatic CRC addicted to the EGFR oncogene (46, 47) 
that do not display mutations in KRAS/NRAS (exons 2–4), BRAF 
(exon 15), or the catalytic subunit (exon 20) of PIK3 (PI3KCA) 
(48). Despite these significant advances, the inevitable emergence 
of drug resistance will ultimately lead to disease progression and, 
eventually, to patient death.
The activation of insulin/IGF-dependent pathways has been 
identified as a critical step contributing to several mechanisms 
of CRC resistance to both conventional and targeted therapeutic 
agents (49).
Scartozzi et  al. reported that high IGF-1 expression corre-
lates with poor clinical outcome in wild-type KRAS metastatic 
CRC patients treated with cetuximab and irinotecan (50). 
They hypothesized that engaging the IGF-1/IGF-1R system 
enabled tumor cells to escape anti-EGFR-mediated treatment 
as a consequence of IGF-1-driven stimulation of the PI3K–Akt 
pathway. Additional evidence also suggests that IGF-1/IGF-1R 
polymorphisms are potential predictive/prognostic markers for 
cetuximab efficacy in metastatic CRC patients presenting wild-
type KRAS (51). Another interesting finding is the reported 
decrease in circulating IGFBP3 levels in CRC patients receiving 
chemotherapy that develop disease progression (Figure  2A) 
(52). As Ohashi et  al. have previously shown an increase in 
matrix metallopeptidase 7 (MMP7) in CRC cells unresponsive 
to chemotherapy, these findings imply that MMP7 could medi-
ate IGFBP3 degradation and enhancement of IGF-dependent 
cancer cell survival and proliferation (53). Hence, the concur-
rent increased expression of IGF-1 and MMP7 may be employed 
as a new marker predicting poor progression-free and OS 
amongst patients with wild-type KRAS and BRAF (52). IGF-2 
is also highly overexpressed in a fraction of CRCs (54) and its 
activation of the IGF-1R reduces CRC cells response to EGFR 
inhibition (Figure 2B).
Besides causing overt drug resistance, parallel signals can 
also induce partial desensitization to treatment. For example, 
hyperactivation of the IGF-Rs together with HER2 and MET 
represents another mechanism adopted by CRC cells to escape 
EGFR oncogene dependency (55–57). Indeed, increased IGF-1R 
signaling has been often associated with low sensitivity to EGFR 
blockade (58, 59). An analysis of the functional cross-talk 
between the IGF-1R and the EGFR has shown that activation of 
IGF-1R downstream signaling is crucial for the mitogenic and 
transforming activity of EGFR (60). Both cetuximab and panitu-
mumab inhibit ligand binding to EGFR, thereby suppressing its 
downstream signaling. Consequently, IGF-1-driven stimulation 
of the PI3K/Akt pathway provides a rational explanation for at 
least part of the lack of efficacy observed in a notable fraction 
of patients with wild-type KRAS tumors treated with EGFR-
targeting monoclonal antibodies (Figure  2C). Finally, IGF-1R 
signaling results in increased expression of the multidrug-
resistance-associated protein 2 (MRP-2), which reduces the 
intracellular concentrations of multiple cytotoxic drugs (61). 
In  vitro silencing of the IGF-1R suppresses MRP-2 in CRC 
cells, thereby increasing the intracellular drug concentration of 
5-Fluorouracil, Mitomycin C, Oxaliplatin, and Vincristine. This 
effect is also mediated by the PI3K/Akt pathway, which causes 
nuclear translocation of nuclear factor-like 2 and reduces MRP-2 
expression (Figure 2D) (62).
Despite promising preclinical evidence, recent trials in meta-
static CRC patients with wild-type KRAS have shown no benefit 
from the combination of anti-EGFR and anti-IGF1-R-directed 
therapies as compared with EGFR-targeted monotherapy (45, 
63). The reasons for these discrepancies are not currently under-
stood and there is still considerable discussion about the validity 
of IGFs and IGF-1R as viable therapeutic targets in CRC. The 
identification of predictive biomarkers will be of crucial impor-
tance for the further development of innovative therapies based 
on anti-IGF-1/2 or anti-IGF-1R agents (64).
COnCLUSiOn
The insulin/IGF system plays a pivotal role in the pathogenesis, 
progression, and prognosis of CRC.
Solid epidemiological and biological evidence indicates that 
hyperactivation of the insulin/IR pathway represents an early step 
in colon cancerogenesis, establishing both mitogenic and pro-
angiogenic signals that favor neoplastic transformation of normal 
colorectal epithelial cells. That the insulin/IR axis is actively 
involved in CRC development is confirmed by the increased 
invasiveness and inferior outcome of patients displaying elevated 
IRS-1 and IRS-2 expression.
Likewise, IGFs/IGF-1R signaling is highly active in CRC, 
contributing to the activation of multiple pathways that increase 
the aggressiveness of the tumor phenotype. As expression of the 
IGF-1R gene is partially regulated by the p53 paralogs p63 and 
p73, mutations, deletions, epigenetic silencing, or post-transla-
tional inactivation of these tumor suppressors further unleash the 
oncogenic potential of the IGF-1R in CRC. The inferior prognosis 
of CRC patients expressing low IGFBP3 or high levels of IGFBP2 
suggests that IGFBPs are also implicated in CRC tumorigenesis, 
either operating as negative regulators of IGFs activity or exerting 
IGF-independent effects on cancer growth.
The insulin/IGF system also contributes to CRC resistance 
to both conventional and targeted anti-cancer agents, leading to 
increased PI3K/Akt signaling that hinders the apoptotic signals 
triggered by chemotherapeutic drugs and desensitizes CRC cells 
to the effect of anti-EGFR antibodies. This may at least partially 
explain the inferior response rates of a subset of metastatic CRC 
patients presenting wild-type KRAS/NRAS, BRAF, or PI3KCA to 
these pharmacological agents.
Finally, the detection of IR/IGF-R HRs adds an additional 
layer of complexity to these intricate signaling networks.
FiGURe 2 | The insulin/iGF system and colorectal cancer resistance to therapy. Mechanisms leading to resistance to different therapeutic agents employed 
in colorectal cancer treatment include (A) increase of MMP7 expression causing IGFBP3 proteolytic degradation and subsequent increase in free circulating IGF-1, 
(B) IGF-2 overexpression, (C) IGF-1R-mediated PI3K/Akt signaling determining (D) nuclear translocation of nuclear factor E2-related factor-2 (Nrf-2) and subsequent 
induction of MRP-2 expression. The increased drug efflux caused by MRP-2 reduces intracellular drug concentrations.
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Numerous agents against insulin/IGF system have been 
tested and even if most of the new compounds performed 
well in preclinical and early clinical studies, when used in 
phase II and III trials, they showed disappointing results. 
Only a detailed understanding of the multifaceted role of the 
various components of the insulin/IGF system and the valida-
tion of predictive biomarkers will allow the appropriate and 
successful use of anti IGF-1/2 or anti-IGF1R drugs, alone or 
in combination with other agents, for the treatment of CRC 
patients.
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